CDMO News
Ayrmid Pharma and RoslinCT Announces Intent to Partner for Omisirge Manufacturing
Ayrmid Pharma Ltd., a cell therapy company developing cellular therapeutics, has announced its intent to partner with RoslinCT, a contract development and manufacturing organisation (CDMO), for the commercial production of Omisirge. Omisirge, a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy, was FDA-approved
11 March 2025